Prognosis and outcome of non-hodgkin lymphoma in primary sjögren syndrome

Medicine

Volumn 91, Issue 1, 2012, Pages 1-9

  Voulgarelis, Michael ^a   Ziakas, Panayiotis D ^a   Papageorgiou, Aristea ^a   Baimpa, Evangelia ^a   Tzioufas, Athanasios G ^a   Moutsopoulos, Haralampos M ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; KIDNEY FAILURE; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NODAL MARGINAL ZONE LYMPHOMA; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEPSIS; SIDE EFFECT; SJOEGREN SYNDROME; STANDARDIZED MORTALITY RATIO;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SJOGREN'S SYNDROME; TREATMENT OUTCOME;

EID: 84855347439     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0b013e31824125e4     Document Type: Article

References (41)

1. Ambrosetti A, Zanotti R, Pattaro C, Lenzi L, Chilosi M, Caramaschi P, Arcaini L, Pasini F, Biasi D, Orlandi E, D'Adda M, Lucioni M, Pizzolo G. Most cases of primary salivary mucosa-associated lymphoid tissue lymphoma are associated either with Sjoegren syndrome or hepatitis C virus infection. Br J Haematol. 2004;126:43-49. (Pubitemid 38859480)
2. Anonymous. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987-994.
3. Baimpa E, Dahabreh IJ, Voulgarelis M, Moutsopoulos HM. Hematologic manifestations and predictors of lymphoma development in primary Sjogren syndrome: clinical and pathophysiologic aspects. Medicine (Baltimore). 2009;88:284-293.
4. Brito-Zeron P, Ramos-Casals M, Bove A, Sentis J, Font J. Predicting adverse outcomes in primary Sjogren's syndrome: identification of prognostic factors. Rheumatology (Oxford). 2007;46:1359-1362. (Pubitemid 47244514)
5. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579-586. (Pubitemid 350002966)
6. Conconi A, Martinelli G, Thieblemont C, Ferreri AJ, Devizzi L, Peccatori F, Ponzoni M, Pedrinis E, Dell'Oro S, Pruneri G, Filipazzi V, Dietrich PY, Gianni AM, Coiffier B, Cavalli F, Zucca E. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood. 2003;102:2741-2745. (Pubitemid 37248842)
7. De Vita S, Dolcetti R, Ferraccioli G, Pivetta B, De Re V, Gloghini A, D'Agosto A, Bartoli E, Carbone A, Boiocchi M. Local cytokine expression in the progression toward B cell malignancy in Sjogren's syndrome. J Rheumatol. 1995;22:1674-1680.
8. Dogan A, Du M, Koulis A, Briskin MJ, Isaacson PG. Expression of lymphocyte homing receptors and vascular addressins in low-grade gastric B-cell lymphomas of mucosa-associated lymphoid tissue. Am J Pathol. 1997;151:1361-1369. (Pubitemid 27479766)
9. Ekstrom Smedby K, Vajdic CM, Falster M, Engels EA, Martinez-Maza O, Turner J, Hjalgrim H, Vineis P, Seniori Costantini A, Bracci PM, Holly EA, Willett E, Spinelli JJ, La Vecchia C, Zheng T, Becker N, De Sanjose S, Chiu BC, Dal Maso L, Cocco P, Maynadie M, Foretova L, Staines A, Brennan P, Davis S, Severson R, Cerhan JR, Breen EC, Birmann B, Grulich AE, Cozen W. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood. 2008;111:4029-4038.
10. Gasparotto D, De Vita S, De Re V, Marzotto A, De Marchi G, Scott CA, Gloghini A, Ferraccioli G, Boiocchi M. Extrasalivary lymphoma development in Sjogren's syndrome: clonal evolution from parotid gland lymphoproliferation and role of local triggering. Arthritis Rheum. 2003;48:3181-3186. (Pubitemid 37409330)
11. Gong Q, Ou Q, Ye S, Lee WP, Cornelius J, Diehl L, Lin WY, Hu Z, Lu Y, Chen Y, Wu Y, Meng YG, Gribling P, Lin Z, Nguyen K, Tran T, Zhang Y, Rosen H, Martin F, Chan AC. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol. 2005;174:817-826. (Pubitemid 40094277)
12. Gordon C, Jayne D, Pusey C, Adu D, Amoura Z, Aringer M, Ballerin J, Cervera R, Calvo-Alen J, Chizzolini C, Dayer J, Doria A, Ferrario F, Floege J, Guillevin L, Haubitz M, Hiepe F, Houssiau F, Lesavre P, Lightstone L, Meroni P, Meyer O, Moulin B, O'Reilly K, Praga M, Schulze-Koops H, Sinico R, Smith K, Tincani A, Vasconcelos C, Hughes G. European consensus statement on the terminology used in the management of lupus glomerulonephritis. Lupus. 2009;18:257-263.
13. Hainsworth JD, Litchy S, Burris HA III, Scullin DC Jr, Corso SW, Yardley DA, Morrissey L, Greco FA. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:4261-4267. (Pubitemid 35191030)
14. Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren's syndrome. Arthritis Rheum. 2002;46:741-747. (Pubitemid 34214255)
15. Jaffe ES. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program. 2009;523-531.
16. Kassan SS, Thomas TL, Moutsopoulos HM, Hoover R, Kimberly RP, Budman DR, Costa J, Decker JL, Chused TM. Increased risk of lymphoma in sicca syndrome. Ann Intern Med. 1978;89: 888-892. (Pubitemid 9087322)
17. Kauppi M, Pukkala E, Isomaki H. Elevated incidence of hematologic malignancies in patients with Sjogren's syndrome compared with patients with rheumatoid arthritis (Finland). Cancer Causes Control. 1997;8:201-204. (Pubitemid 27170375)
18. Lazarus MN, Robinson D, Mak V, Moller H, Isenberg DA. Incidence of cancer in a cohort of patients with primary Sjogren's syndrome. Rheumatology (Oxford). 2006;45:1012-1015. (Pubitemid 44283059)
19. Orditura M, De Vita F, Belli A, Ciaramella F, Musico M, Ferrigno A, Formato R, Abbate G, Diadema MR, Catalano G. Efficacy and safety profile of amifostine in the preoperative combined therapy of esophageal cancer patients. Oncol Rep. 2000;7:397-400.
20. Pavlidis NA, Drosos AA, Papadimitriou C, Talal N, Moutsopoulos HM. Lymphoma in Sjogren's syndrome. Med Pediatr Oncol. 1992;20:279-283.
21. Pijpe J, van Imhoff GW, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K, Vissink A, Kallenberg CG, Bootsma H. Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis Rheum. 2005;52: 2740-2750. (Pubitemid 41369102)
22. Pijpe J, van Imhoff GW, Vissink A, van der Wal JE, Kluin PM, Spijkervet FK, Kallenberg CG, Bootsma H. Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren's syndrome and associated MALT lymphoma. Ann Rheum Dis. 2005;64:958-960. (Pubitemid 40733928)
23. Quartuccio L, Fabris M, Moretti M, Barone F, Bombardieri M, Rupolo M, Lombardi S, Pitzalis C, Beltrami CA, Curcio F, De Vita S. Resistance to rituximab therapy and local BAFF overexpression in Sjogren's syndrome-related myoepithelial sialadenitis and low-grade parotid B-cell lymphoma. Open Rheumatol J. 2008;2:38-43.
24. Ramos-Casals M, Brito-Zeron P, Yague J, Akasbi M, Bautista R, Ruano M, Claver G, Gil V, Font J. Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjogren's syndrome. Rheumatology (Oxford). 2005;44:89-94. (Pubitemid 40124338)
25. Royer B, Cazals-Hatem D, Sibilia J, Agbalika F, Cayuela JM, Soussi T, Maloisel F, Clauvel JP, Brouet JC, Mariette X. Lymphomas in patients with Sjogren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. Blood. 1997;90:766-775. (Pubitemid 27299117)
26. Seror R, Sordet C, Guillevin L, Hachulla E, Masson C, Ittah M, Candon S, Le Guern V, Aouba A, Sibilia J, Gottenberg JE, Mariette X. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome. Ann Rheum Dis. 2007;66: 351-357. (Pubitemid 46579637)
27. Shiozawa E, Norose T, Kaneko K, Yamochi-Onizuka T, Takimoto M, Imawari M, Ota H. Clinicopathological comparison of the World Health Organization/ Wotherspoon score to the Groupe d'Etude des Lymphomes de l'Adult grade for the post-treatment evaluation of gastric mucosa-associated lymphoid tissue lymphoma. J Gastroenterol Hepatol. 2009;24:307-315.
28. Skopouli FN, Dafni U, Ioannidis JP, Moutsopoulos HM. Clinical evolution, and morbidity and mortality of primary Sjogren's syndrome. Semin Arthritis Rheum. 2000;29:296-304. (Pubitemid 30235981)
29. Smedby KE, Hjalgrim H, Askling J, Chang ET, Gregersen H, Porwit-MacDonald A, Sundstrom C, Akerman M, Melbye M, Glimelius B, Adami HO. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst. 2006;98:51-60. (Pubitemid 43057092)
30. Somer BG, Tsai DE, Downs L, Weinstein B, Schuster SJ. Improvement in Sjogren's syndrome following therapy with rituximab for marginal zone lymphoma. Arthritis Rheum. 2003;49:394-398. (Pubitemid 36682408)
31. Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, Jacobsson LT. Lymphoma and other malignancies in primary Sjogren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis. 2006;65:796-803. (Pubitemid 43799181)
32. Theander E, Manthorpe R, Jacobsson LT. Mortality and causes of death in primary Sjogren's syndrome: a prospective cohort study. Arthritis Rheum. 2004;50:1262-1269. (Pubitemid 38480838)
33. Thieblemont C, Berger F, Dumontet C, Moullet I, Bouafia F, Felman P, Salles G, Coiffier B. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood. 2000;95:802-806. (Pubitemid 30062699)
34. Tzioufas AG, Boumba DS, Skopouli FN, Moutsopoulos HM. Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjogren's syndrome. Arthritis Rheum. 1996;39:767-772.
35. Valesini G, Priori R, Bavoillot D, Osborn J, Danieli MG, Del Papa N, Gerli R, Pietrogrande M, Sabbadini MG, Silvestris F, Valsecchi L. Differential risk of non-Hodgkin's lymphoma in Italian patients with primary Sjogren's syndrome. J Rheumatol. 1997;24:2376-2380. (Pubitemid 28005139)
36. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61:554-558. (Pubitemid 34539104)
37. Voulgarelis M, Dafni UG, Isenberg DA, Moutsopoulos HM. Malignant lymphoma in primary Sjogren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjogren's Syndrome. Arthritis Rheum. 1999;42:1765-1772. (Pubitemid 30263648)
38. Voulgarelis M, Giannouli S, Tzioufas AG, Moutsopoulos HM. Long term remission of Sjogren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Ann Rheum Dis. 2006;65:1033-1037. (Pubitemid 44133265)
39. Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med. 2005;165:2337-2344. (Pubitemid 41640845)
40. Zinzani PL, Magagnoli M, Galieni P, Martelli M, Poletti V, Zaja F, Molica S, Zaccaria A, Cantonetti AM, Gentilini P, Guardigni L, Gherlinzoni F, Ribersani M, Bendandi M, Albertini P, Tura S. Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients. J Clin Oncol. 1999;17:1254.
41. Zucca E, Conconi A, Pedrinis E, Cortelazzo S, Motta T, Gospodarowicz MK, Patterson BJ, Ferreri AJ, Ponzoni M, Devizzi L, Giardini R, Pinotti G, Capella C, Zinzani PL, Pileri S, Lopez-Guillermo A, Campo E, Ambrosetti A, Baldini L, Cavalli F. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood. 2003;101: 2489-2495. (Pubitemid 36857603)